Influence of Adrenal Subclinical Hypercortisolism on Hypertension in Patients with Adrenal Incidentaloma

Abstract

Objective:

The purpose of our study was to clarify whether subtle cortisol-producing tumors, such as not only subclinical Cushing’s syndrome (SubCS) but also subclinical hypercortisolism (SH), influence the prevalence of hypertension, since numerous basic research studies have noted that glucocorticoid excess influences blood pressure.

Methods:

80 patients with adrenocortical adenomas (39 women and 41 men; mean age 62.1 years) were enrolled. SubCS was diagnosed using a diagnostic criteria, and SH was diagnosed as the presence of a serum cortisol level greater than 50 nmol/L following 1-mg dexamethasone suppression test (DST).

Results:

SubCS, SH, or non-functioning adrenocortical adenoma (NF) was diagnosed in 14, 13, or 53 patients, respectively. The prevalence of hypertension differed significantly among the diagnoses (SubCS, 78.6%; SH, 84.6%; NF, 39.6%; P=0.002), whereas no differences in other clinical characteristics such as age, sex, or waist girth were observed. The patients with SH had an 11.7-fold increased risk (95% confidence interval: 1.9–72.7, P=0.009) and those with SubCS had a 9.5-fold increased risk (95% confidence interval: 1.9–48.3, P=0.007) for hypertension compared to those with NF using a multivariate analysis.

Conclusion:

We demonstrated that subtle cortisol-producing tumors, such as SH as well as SubCS, were an independent risk factor for hypertension. The cut-off value of the 1-mg DST would be appropriate to predict the development of hypertension.

Key words

subclinical Cushing’s syndrome - hypertension - cortisol - adrenal tumor

• References

• 1 Barzon L, Sonino N, Fallo F et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149: 273-285
• 2 Catargi B, Rigalleau V, Poussin A et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab 2003; 88: 5808-5813
• 3 Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 2011; 96: 1223-1136
• 4 Chiodini I, Di Lembo S, Morelli V et al. Hypothalamic-pituitary-adrenal activity in type 2 diabetes mellitus: role of autonomic imbalance. Metabolism 2006; 55: 1135-1140
• 5 Chiodini I, Torlontano M, Scillitani A et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol 2005; 153: 837-844
• 6 Crapo L. Cushing’s syndrome: a review of diagnostic tests. Metabolism 1979; 28: 955-977
• 7 Erbil Y, Ademoğlu E, Ozbey N et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006; 30: 1665-1671
• 8 Hamm LL, Hering-Smith KS. Pivotal role of the kidney in hypertension. Am J Med Sci 2010; 340: 30-32
• 9 Kubo M, Kiyohara Y, Kato I et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349-2354
• 10 Libè R, DallAsta C, Barbetta L et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 2002; 147: 489-494
• 11 Liu Y, Mladinov D, Pietrusz JL et al. Glucocorticoid response elements and 11 beta-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardiovasc Res 2009; 81: 140-147
• 12 Mantero F, Terzolo M, Arnaldi G et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644
• 13 Mitchell IC, Auchus RJ, Juneja K et al. “Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 2007; 142: 900-905
• 14 Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 15 Rossi GP, Andreis PG, Colonna S et al. Endothelin-1[1-31]: a novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. J Clin Endocrinol Metab 2002; 87: 322-328
• 16 Rossi R, Tauchmanova L, Luciano A et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000; 85: 1440-1448
• 17 Stamler J, Elliott P, Kesteloot H et al. Inverse relation of dietary protein markers with blood pressure. Findings for 10 020 men and women in the INTERSALT Study. INTERSALT Cooperative Research Group. INTERnational study of SALT and blood pressure. Circulation 1996; 94: 1629-1634
• 18 Terzolo M, Bovio S, Pia A et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol 2005; 153: 307-315
• 19 Terzolo M, Pia A, Alì A et al. Adrenal incidentaloma: a new cause of the metabolic syndrome?. J Clin Endocrinol Metab 2002; 87: 998-1003
• 20 Terzolo M, Reimondo G, Bovio S et al. Subclinical Cushing’s syndrome. Pituitary 2004; 7: 217-223
• 21 Valli N, Catargi B, Ronci N et al. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol 2001; 144: 401-408
• 22 Vassilatou E, Vryonidou A, Michalopoulou S et al. Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol 2009; 70: 674-679
• 23 Wood PJ, Barth JH, Freedman DB et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome – recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 1997; 34: 222-229
• 24 Xiao D, Huang X, Bae S et al. Cortisol-mediated potentiation of uterine artery contractility: effect of pregnancy. Am J Physiol Heart Circ Physiol 2002; 283: H238-H246